The FDA granted investigational drug clearance to HG202, a CRISPR/Cas13Y RNA-editing therapy for neovascular age-related macular degeneration, according to a press release from HuidaGene.
According to the release, HG202 is the first CRISPR/Cas13Y RNA-targeting therapy in clinical development as well as the only clinical-stage CRISPR RNA-editing therapy for AMD.
After promising results from preclinical studies, HuidaGene is initiating a phase 1 dose-finding trial for the therapy.
“This open IND for HG202 by the U.S. FDA — the first regulator to have cleared CRISPR/Cas13 for clinical development — represents an important milestone for HuidaGene and the entire CRISPR gene-editing field of RNA editing,”
Source: Healio